Meta-analysis is no substitute for a comprehensive national registry.
Clin Rheumatol
; 26(7): 1134-5, 2007 Jul.
Article
em En
| MEDLINE
| ID: mdl-17115099
ABSTRACT
Anti-tumor necrosis factor alpha (TNF-alpha) agents have become an established treatment option for rheumatoid arthritis (RA), but are not without risks. As TNF-alpha has a role in tumour surveillance, anti-TNF-alpha blockade could potentially increase the risk of malignancy. Recent meta-analysis by Bongartz et al. (JAMA 2952275-2285, 2006) reported an increase in the incidence of malignancy attributed to anti-TNF-alpha antibodies, and the information has quickly and uncritically reached several secondary sources with huge effects on public perception of risks related to anti-TNF-alpha therapy. In contrast, the results from the British Society for Rheumatology Biologics Register show that in clinical practice, anti-TNF-alpha therapy in RA does not appear to increase the risk of malignancy in those patients with low risk of malignancy. We discuss the issues emerging from these published data and suggest caution against giving weight to meta-analysis of short-term drug studies.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Sistema de Registros
/
Metanálise como Assunto
/
Fator de Necrose Tumoral alfa
/
Anticorpos Monoclonais
/
Neoplasias
Tipo de estudo:
Systematic_reviews
Limite:
Humans
País/Região como assunto:
Europa
Idioma:
En
Ano de publicação:
2007
Tipo de documento:
Article